Drug Profile
Infliximab biosimilar - Amgen
Alternative Names: ABP-710; AVSOLALatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Amgen
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- No development reported Inflammation; Rheumatic disorders
Most Recent Events
- 30 Nov 2022 No development reported - Phase-III for Rheumatoid arthritis (Adjunctive treatment) in Australia (IV) (Amgen pipeline, November 2022)
- 12 Mar 2020 Registered for Rheumatoid arthritis (Adjunctive treatment) in Canada (IV)
- 06 Dec 2019 Registered for Ankylosing spondylitis (In adults) in USA (IV)